Want to see DBVT full AI Analyst Report?
DBVT Stock Chart & Stats
$21.34
$0.34(9.80%)
At close: 4:00 PM EST
$21.34
$0.34(9.80%)
Day’s Range― - ―
52-Week Range$8.51 - $26.19
Previous CloseN/A
Volume52.91K
Average Volume (3M)287.11K
Market Cap
$878.53M
Enterprise Value$1.09K
Total Cash (Recent Filing)$174.90M
Total Debt (Recent Filing)$7.70M
Price to Earnings (P/E)―
Beta0.07
Next Earnings
Oct 28, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding59,212,300
10 Day Avg. Volume239,371
30 Day Avg. Volume287,107
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)9.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.67
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$47.80Price Target Upside123.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$4.36M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthThe company’s low debt relative to equity and sizable assets provide a durable multi‑quarter cushion against operating losses. That balance sheet flexibility reduces near‑term solvency risk, giving management runway to complete regulatory work and execute commercialization planning if approval is achieved.
Regulatory Engagement De‑riskingIterative, collaborative FDA engagement that reportedly did not require new efficacy data and instead focused on organizing existing CMC and biostatistical materials materially reduces regulatory ambiguity. This clarifies the path to a BLA submission and lowers a key structural approval risk for commercialization.
Differentiated EPIT Platform & Launch PrepViaskin’s epicutaneous immunotherapy patch is a differentiated, potentially multi‑allergen platform addressing food allergies. Management’s deliberate investments in launch readiness signal scalable go‑to‑market preparation, which could convert clinical success into enduring commercial capabilities if regulatory approval is secured.
Bears Say
No Revenue & Large LossesThe company generated no material revenue over the trailing twelve months while net losses widened materially, meaning operations lack internal cash inflows. Persistent large losses erode shareholder equity over time and create structural dependence on external capital to sustain R&D and commercialization efforts.
Accelerating Cash Burn & Financing RiskOperating and free cash flow have deteriorated sharply, indicating accelerating cash burn. Maintaining clinical programs and planned launch investments will require material financing, increasing dilution and constraining strategic flexibility; access to capital is a recurring structural risk for execution.
Clinical‑stage Revenue Visibility & Timing RiskAs a clinical‑stage biotech with no commercial track record, revenue and profitability depend on regulatory approval and successful market uptake. Historical revenue lapses and extended timelines create persistent timing and execution risk that can delay or reduce long‑term returns even if approval is eventually obtained.
DBV Technologies SA - American News
DBVT FAQ
What was DBV Technologies S.A. - American Depositary Shares’s price range in the past 12 months?
DBV Technologies S.A. - American Depositary Shares lowest stock price was $8.51 and its highest was $26.18 in the past 12 months.
What is DBV Technologies S.A. - American Depositary Shares’s market cap?
DBV Technologies S.A. - American Depositary Shares’s market cap is $878.53M.
When is DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date?
DBV Technologies S.A. - American Depositary Shares’s upcoming earnings report date is Oct 28, 2026 which is in 99 days.
How were DBV Technologies S.A. - American Depositary Shares’s earnings last quarter?
DBV Technologies S.A. - American Depositary Shares released its earnings results on Jul 16, 2026. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.012.
Is DBV Technologies S.A. - American Depositary Shares overvalued?
According to Wall Street analysts DBV Technologies S.A. - American Depositary Shares’s price is currently Undervalued.
Does DBV Technologies S.A. - American Depositary Shares pay dividends?
DBV Technologies S.A. - American Depositary Shares does not currently pay dividends.
What is DBV Technologies S.A. - American Depositary Shares’s EPS estimate?
DBV Technologies S.A. - American Depositary Shares’s EPS estimate is -0.14.
How many shares outstanding does DBV Technologies S.A. - American Depositary Shares have?
DBV Technologies S.A. - American Depositary Shares has 59,212,300 shares outstanding.
What happened to DBV Technologies S.A. - American Depositary Shares’s price movement after its last earnings report?
DBV Technologies S.A. - American Depositary Shares reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went down -1.077%.
Which hedge fund is a major shareholder of DBV Technologies S.A. - American Depositary Shares?
Currently, no hedge funds are holding shares in DBVT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DBV Technologies SA - American Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.80 (123.99% Upside)
$47.80 (123.99% Upside)
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
55.62%
Trailing 12-Months
Company Description
DBV Technologies S.A. - American Depositary Shares
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBVT Stock 12 Month Forecast
Average Price Target
$47.80
▲(123.99% Upside)
Technical Analysis
Larimar Therapeutics
―
Korro Bio
―
4D Molecular Therapeutics
―
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
62.50% Insiders
2.44% Mutual Funds
0.04% Other Institutional Investors
34.95% Public Companies and
Individual Investors